Marker Therapeutics shares are trading higher after it reported first patient was treated in the company's Phase 1 APOLLO trial of MT-601 for lymphoma patients.
Portfolio Pulse from Benzinga Newsdesk
Marker Therapeutics announced that the first patient has been treated in its Phase 1 APOLLO trial of MT-601 for lymphoma patients, leading to a rise in its share price.
June 12, 2023 | 2:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Marker Therapeutics' shares are trading higher after the first patient was treated in the Phase 1 APOLLO trial of MT-601 for lymphoma patients.
The initiation of the Phase 1 APOLLO trial of MT-601 for lymphoma patients is a significant milestone for Marker Therapeutics. This positive development has led to an increase in the company's share price, reflecting investor optimism about the potential success of the trial and the future prospects of MT-601.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100